Overcoming resistance to osimertinib in non–small cell lung cancer: Hopes, doubts, and in‐between | Zendy

Passaro Antonio | Zendy; Malapelle Umberto | Zendy; Attili Ilaria | Zendy; Marinis Filippo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Overcoming resistance to osimertinib in non–small cell lung cancer: Hopes, doubts, and in‐between

Author(s) -

Passaro Antonio,

Malapelle Umberto,

Attili Ilaria,

Marinis Filippo

Publication year - 2020

Publication title -

cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.052

H-Index - 304

eISSN - 1097-0142

pISSN - 0008-543X

DOI - 10.1002/cncr.32810

Subject(s) - osimertinib , medicine , lung cancer , cornerstone , identification (biology) , tyrosine kinase , resistance (ecology) , cancer , intensive care medicine , cancer research , adenocarcinoma , receptor , biology , ros1 , ecology , art , botany , visual arts

The identification of resistance mechanisms to third‐generation tyrosine kinase inhibitors—in particular osimertinib—should be considered as a cornerstone for understanding treatment individualization in an era of precision medicine, potentially improving patient outcomes significantly through a multifactorial strategy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research